News:Valbiotis announced positive results in the bioavailability and mode of action clinical study conducted on TOTUM--854 against high blood pressure, the number one cardiovascular risk factor worldwide. The mode of action results demonstrate a protective effect of TOTUM--854 on vascular wall cells and a reduction in angiotensin I-converting enzyme (ACE1) activity in humans. These robust data confirm the potential of TOTUM--854 to reduce blood pressure at the earliest stages of arterial hypertension, which affect 123 million people in the US and Europe(1) .

They hold great promise for the late-stage clinical development of TOTUM--854.